Abbott Laboratories Management Discusses Q2 2012 Results - Earnings Call ... Seeking Alpha Daclizumab is a next-generation biologic for MS, currently in late-stage development with a partner company. Results from the Phase III study are expected in 2014. ABT-126 is our alpha7 NRR. It's currently in mid-stage development for Alzheimer's ... |
